Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 6/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.37 |
| ▸ | CDC25B | P30305 | 8/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605161 | 0.93 | SELP (0.40) | SELPCA1CA2CA9PTPN1 | |
| SCHEMBL2605158 | 0.92 | SELP (0.41) | SELPCA1CA2CA9PTPN1 | |
| SCHEMBL2605166 | 0.89 | SELP (0.43) | SELPCA1CA2CA9PTPN1 | |
| SCHEMBL2605156 | 0.84 | SELP (0.47) | SELPCA1CA2CA9PTPN1 | |
| SCHEMBL2605154 | 0.83 | SSTR1 (0.43) | SELPCA1CA2CA9PTPN1 | |
| SCHEMBL2605152 | 0.80 | TNF (0.47) | SELPPTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL2605162 | 0.77 | SELP (0.45) | SELPCA1CA2CA9PTPN1 | |
| SCHEMBL2605159 | 0.76 | SELP (0.46) | SELPCA1CA2CA9PTPN1 | |
| SCHEMBL14477819 | 0.73 | SELP (0.37) | SELP | |
| SCHEMBL2605165 | 0.72 | SELP (0.47) | SELPCA1CA2CA9PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163705-B2 | Glycolipid and use thereof | RIKEN (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090221516-A1 | NOVEL GLYCOLIPID AND USE THEREOF | RIKEN (JP) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221516-A1 | NOVEL GLYCOLIPID AND USE THEREOF | IL4, IL2, IL5 | SELP 279/4885CA1 2002/4885CA2 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.